Miguel G Uriol-Rivera, Aina Obrador-Mulet, Maria Rosa Juliá, Vanessa Daza-Cajigal, Olga Delgado-Sanchez, Angel Garcia Alvarez, Ana Gomez-Lobon, Paula Carrillo-Garcia, Carlos Saus-Sarrias, Cristina Gómez-Cobo, Daniel Ramis-Cabrer, Joan Gasco Company, Javier Molina-Infante
There is no established treatment for progressive IgA nephropathy refractory to steroids and immunosuppressant drugs (r-IgAN). Interleukin 17 (IL-17) blockade has garnered interest in immune-mediated diseases involving the gut-kidney axis. However, single IL-17A inhibition induced paradoxical effects in patients with Crohn's disease and some cases of de novo glomerulonephritis, possibly due to the complete Th1 cell response, along with the concomitant downregulation of regulatory T cells (Tregs). Seven r-IgAN patients were treated with at least six months of oral paricalcitol, followed by the addition of subcutaneous anti-IL-17A (secukinumab)...
February 28, 2024: Scientific Reports